Thyme Care, the leading value-based cancer care enabler, has raised $97 million in Series D funding, further solidifying its position as a market leader in oncology care transformation. This round brings Thyme Care’s total capital raised to $275 million.
The fundraise was led by existing investors CVS Health® Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures. New strategic investors joining this round include Morgan Health (a JPMorganChase division), Humana, Texas Oncology, and Memorial Hermann Health System—a coalition representing payers, providers, employers, and health systems across the oncology ecosystem.
Scaling Value-Based Cancer Care
“This raise is overwhelmingly backed by strategic investors across the oncology care delivery landscape, including payers, providers, employers, and health systems who deeply understand the complex needs of oncology populations and who see firsthand the impact of Thyme Care’s model,” said Thyme Care President and Chief Operating Officer Brad Diephuis, MD.
“This is evidence that oncology can lead the way in building scalable models of shared accountability and impact that healthcare has long needed.”
Robin Shah, Co-Founder and Chief Executive Officer, added:
“The system was not designed for people with cancer, and too often patients fall through the cracks. My co-founder, Dr. Bobby Green, and I have seen this from the inside out for decades. We’ve witnessed it at the bedside in community practices and in building national infrastructures at Flatiron Health and OneOncology, and we founded Thyme Care to change it. Our next chapter is about scaling what works while exploring new ways to tackle the barriers that still make cancer care harder than it needs to be.”
Building a Connected Cancer Care Infrastructure
Founded in 2020, Thyme Care has built an integrated oncology infrastructure that reduces friction across the system. By aligning incentives with payers and working with over 1,000 oncologists nationwide, the company:
-
Reduces administrative burden on practices.
-
Supports higher-value drug choices and clinical collaboration.
-
Integrates palliative care and survivorship programs directly into the cancer care journey.
This approach enables earlier interventions, fewer delays, and continuous patient support, resulting in a more connected, compassionate care experience.
Proven Systemic Impact
Thyme Care’s model has demonstrated transformative results across cost, patient experience, and provider efficiency:
-
Connected patient support: ~90% of members feel more supported by Thyme Care’s care teams, with 72% proactively sharing health updates—nearly double the industry average.
-
Avoiding costly complications: Members who completed electronic patient-reported outcome (ePRO) surveys were 40% less likely to visit the ER and had 19% fewer hospital admissions.
-
Reducing provider burden: One partner oncology practice saved nearly 2,000 staff hours in a single year, allowing providers to focus more on direct patient care.
Leveraging AI for Scalable Cancer Care
Artificial intelligence is a key accelerator in Thyme Care’s model. By automating documentation, surfacing real-time insights, and simplifying complex data, AI enables:
-
Faster clinical decision-making
-
Reduced administrative load
-
More time for providers to focus on patients
This positions AI not just as a tool, but as an “invisible operating layer” that makes high-quality, scalable cancer care possible.
Strategic Investor Endorsements
“Employers increasingly identify cancer as a top driver of their health care spend. At the same time, they care deeply about offering their employees access to high-quality, personalized cancer care – given the heavy burden that a diagnosis places on patients and their families,” said Dan Mendelson, CEO of Morgan Health.
“Thyme Care can balance these needs and is already making early progress with Fortune 500 companies. They’ve demonstrated better coordination of patient care, improved outcomes and reduced costs. This approach aligns directly with our mission to scale specialist-led, value-based care for complex conditions in employer-sponsored insurance.“
“We continue to invest in Thyme Care because of the meaningful impact their model has on improving the lives of people with cancer,” said Vijay Patel, Managing Partner, CVS Health Ventures.
“Through their technology, partnerships, and national scale, we’ve seen how Thyme Care can help deliver more coordinated interventions and a care experience that feels more connected, human, and affordable.“
The Road Ahead
With this new round of funding, Thyme Care is poised to scale its proven oncology model further, strengthen payer-provider collaborations, and continue breaking down barriers in cancer care delivery—ensuring that patients receive timely, compassionate, and sustainable care throughout their journey.